Meldonium vs PT-141
Moderate Research vs FDA Approved
monitor Mechanism-based · 51% Both Meldonium and PT-141 can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
Meldonium PT-141
Weight 146.19 Da —
Half-life ~4-6 hours ~2.7 hours
Type Hydrazinium derivative (C6H14N2O2) Melanocortin receptor agonist
Key Benefits
Meldonium
01 Cardioprotective effects through metabolic optimization under ischemic conditions
02 Shifts cardiac energy metabolism from fatty acid oxidation to more oxygen-efficient glucose oxidation
03 Reduces accumulation of toxic fatty acid intermediates (long-chain acylcarnitines) in heart tissue
04 Promotes nitric oxide synthesis and endothelial function via GBB accumulation
05 May improve exercise capacity and reduce recovery time through enhanced glucose utilization
06 Used as adjunctive cardiac protection during anabolic steroid cycles to mitigate androgen-induced cardiotoxicity
07 Well-established safety profile in Eastern European clinical use spanning over 30 years
PT-141
01 FDA-approved pharmaceutical route
02 Predictable absorption profile
03 Effective for both male and female sexual dysfunction
04 Works within 45 minutes
05 Effective in PDE5 inhibitor-resistant cases
06 Central mechanism (not dependent on blood flow)
Dosing Protocols
Meldonium
500-1000 mg/day / Once or twice daily (oral)
PT-141
Women: 1.75mg (FDA-approved); Men: 1-2mg; Start 0.5mg test dose for tolerance / As needed before sexual activity; max 1 dose per 24 hours
Female HSDD (FDA-approved) 1.75mg As needed, max 1 dose/24hr
Male Erectile Dysfunction 1-2mg As needed, 45-60min before activity
Female Arousal Disorder 0.75-1.25mg As needed, max 1 dose/24hr
Low Starting Dose 0.5mg Test dose for tolerance assessment
Side Effects
Meldonium
Mild gastrointestinal discomfort (nausea, dyspepsia, or stomach upset -- typically transient and dose-dependent)
Occasional heartburn or acid reflux, especially at higher doses or when taken on an empty stomach
PT-141
Nausea (40%)
Flushing (20%)
Headache (11%)
Injection site reactions
Contraindications
Known hypersensitivity to meldonium or any excipients
Pregnancy or breastfeeding (insufficient safety data)
Individuals under 18 years of age
Severe hepatic or renal impairment (limited pharmacokinetic data in these populations)
Increased intracranial pressure (listed as a contraindication in some regional prescribing information)
Uncontrolled hypertension
Cardiovascular disease
Use of nitrate medications
Pregnancy or breastfeeding
Research Evidence
Meldonium PT-141
Status Moderate Research FDA Approved
References 4 studies 4 studies
Latest 2016 2022
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.